ASX Announcement

29 October 2026

September Quarter Trading and Operational Update

Hydrix Limited ('Hydrix' or 'the Company') (ASX: HYD) reports double-digit year-on-year quarterly revenue growth, sales of major engineering contracts, and an advancing Defence technology commercialisation strategy.

September Quarter Business Activity Highlights

Hydrix Services

- **Contract sales** of **$4.1 million** and quarterly **revenue** of **$2.8 million, up 28.1%** on the previous quarter and **11.6%** on the prior corresponding quarter.
- Appointed a **US-based** Vice President of Business Development to accelerate sales growth.

Hydrix Medical

- Recorded a **$0.65 million contract sale** to the National Heart Centre Singapore, representing the **first commercial sale of the Implicity remote cardiac monitoring platform in the Asia-Pacific region**. This milestone establishes a major regional reference customer, validates Hydrix Medical's commercialisation strategy and provides a foundation for further sales and recurring revenue growth across the region.

Hydrix Defence

- **Delivered** the first major NIOA counter-UAS payload program milestone under ASCA's Mission Syracuse, ahead of planned December-quarter flight trials.
- **Evaluated twelve** Defence technology development and commercialisation opportunities, including proprietary sensing and radio-frequency technologies. **Four initiatives** are in active technical and market opportunity review.
- **Engaged** senior Defence and government representatives at Land Forces 2026 and briefed ASCA on Hydrix's sovereign engineering capabilities and Defence IP strategy.

Executive Chairman Gavin Coote said:

"The September quarter delivered an encouraging start to FY27, with double-digit year-on-year revenue growth and $4.1 million in Services contract sales supporting near-term revenue outlook."

"Recent contract wins are translating into engineering revenues, including the ramp-up of the Remedy Robotics program. Our expanded presence in the United States will strengthen engagement with customers in the world's largest medical technology market."

"Successful milestone delivery on the NIOA counter-UAS program demonstrates our capability in complex, safety-critical Defence technology engineering. We are making meaningful progress evaluating selected

Defence technology opportunities, with a focus on developing and commercialising Australian-owned intellectual property."

"The first commercial sale of the Implicity platform in Asia-Pacific is another important milestone, establishing a reference customer in Singapore and a foundation for recurring revenue growth."

"Our focus remains on growing engineering services revenue, improving profitability and leveraging our engineering team to develop proprietary technologies that can create longer-term value for shareholders."

SEPTEMBER QUARTER OPERATING HIGHLIGHTS

Hydrix Services

Services delivered $2.8 million in September-quarter revenue, representing growth of 28.1% quarter-on-quarter and 11.6% year-on-year. Contract sales of $4.1 million support ongoing development activity and the Company's near-term revenue outlook. The appointment of a US-based business development leader supports direct engagement with medical technology customers in that market.

Engineering work on the Remedy program progressed during the quarter, drawing on Hydrix's capabilities in embedded electronics, safety-critical software, systems integration and verification for regulated medical robotics.



The Remedy Robotics N1 System in use during the world's first fully remote neurointerventional procedure. *Image source: Remedy Robotics*

Hydrix Medical

Hydrix Medical secured its first commercial sale of the Implicity remote cardiac monitoring platform in the Asia-Pacific region, with a multi-year contract valued at approximately $0.65 million with the prestigious National Heart Centre Singapore (NHCS).

The agreement establishes an important regional reference customer and provides a foundation for further commercial expansion and recurring revenue growth across Australia, Singapore and New Zealand.



Hydrix Defence

Hydrix successfully delivered the first benchtop integration system under its A$1.2 million development contract with NIOA.

Rudi Bekker, NIOA VP Engineering said: “The program stage delivery demonstrates Hydrix’s defence technology expertise in mission-critical electronics, embedded software and complex systems engineering.”



Hydrix is developing the Power & Interface Controller (PIC) for NIOA’s kinetic effector payload. Image source: NIOA

The Hydrix team briefs **Deputy Prime Minister & Minister for Defence Richard Marles**, Chief of the Defence Force Admiral Mark Hammond and Chief of Army Lieutenant General Susan Coyle at Land Forces 2026 in Perth.




Image source: Hydrix

Corporate

Hydrix closed the September quarter with cash on hand of $1.5 million. Cash receipts from customers totalled $2.5 million, with net cash used in operating activities of $1.1 million and net cash used in financing activities of $0.3 million.

Cash utilisation during the quarter was impacted by customer payment timing and several one-off payments.

- Customer receipts were delayed on projects where customers are raising capital to fund development activities or where payments are linked to project milestones. The Company anticipates these payments will be brought up to date during the December quarter.
- One-off cash payments included costs relating to the June quarter capital raise and the transition from quarterly to monthly superannuation payments from 1 July, resulting in two quarters of superannuation being paid during the September quarter.

Outlook

The Company's immediate priorities are to convert its contracted projects and sales pipeline into revenue growth, advance selected Defence technology initiatives and build on the commercial progress achieved by Hydrix Medical.

Hydrix remains focused on scaling engineering services revenue within its existing operating infrastructure, improving profitability and pursuing technology ownership aimed at generating larger and more enduring revenue streams.

Ends ----

This announcement is authorised for release by the Board of Directors of Hydrix Limited.

For more information, please contact:

Hydrix Enquiries:	Media Enquiries:	Investor Enquiries:
Alan Morris	**Rod North**	**Niv Dagan**
Marketing Director	Managing Director	Executive Director
Hydrix Ltd	**Bourse Communications**	**Peak Asset Management**
alan.morris@hydrix.com	rod@boursecommunications.com.au	niv.dagan@peakassetmanagement.com.au
+61 3 9550 8100	+61 3 9510 8309	M 0402 912 198

About Hydrix Limited

Hydrix Limited (ASX: HYD) is an Australian technology company operating across medical technology, defence, industrial and mining. The Group combines multidisciplinary engineering, technology investment, intellectual property development and commercialisation to create long-term value for customers and shareholders.

Latest **Hydrix Limited** investor updates: www.hydrixltd.com.

Explore **Hydrix Services:** www.hydrix.com and on LinkedIn.

Learn about **Hydrix Defence:** Investor Presentation.

Discover **Hydrix Medical** remote cardiac monitoring: www.hydrixmedical.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Hydrix Limited

ABN	**Quarter ended ("current quarter")**
84 060 369 048	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	2,553	2,553
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(124)	(124)
	(c) advertising and marketing	(71)	(71)
	(d) leased assets	(148)	(148)
	(e) staff costs	(2,805)	(2,805)
	(f) administration and corporate costs	(548)	(548)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	6	6
1.5	Interest and other costs of finance paid	(9)	(9)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,146)**	**(1,146)**
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(6)	(6)
	(d) investments	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(6)**	**(6)**
3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(249)	(249)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(62)	(62)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**(311)**	**(311)**
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	2,958	2,958
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,146)	(1,146)

	Consolidated statement of cash flows	Current quarter $A'000	Year to date (3 months) $A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(6)	(6)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(311)	(311)
4.5	Effect of movement in exchange rates on cash held	-	
4.6	**Cash and cash equivalents at end of period**	**1,495**	**1,495**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	1,495	2,958
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,495**	**2,958**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	222
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes full-time salary payments to the Executive Chairman and Director Fees paid to the Board of Directors for services provided.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	6,000	6,000
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**6,000**	**6,000**

7.5 **Unused financing facilities available at quarter end ($A'000)**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Lender	Loan Amount	Interest rate (p.a)	Maturity date	Security
John W King Nominees[1,7]	$ 1,500,000	10.0%	26/11/2026[8]	Unsecured
John W King Nominees[1]	$ 500,000	11.0%	26/11/2026[8]	Unsecured
John W King Nominees[1]	$ 75,000	12.0%	26/11/2026[8]	Unsecured
John W King Nominees[1]	$ 1,975,000	12.0%	1/10/2027	Unsecured
Invia Custodian Pty Limited[2,7]	$ 500,000	10.0%	26/11/2026[8]	Unsecured
Invia Custodian Pty Limited[3]	$ 500,000	12.0%	26/11/2026[8]	Unsecured
PAJ Lewis Pty Ltd[3]	$ 100,000	12.0%	26/11/2026[8]	Unsecured
PAJ Lewis Superannuation Fund Pty Ltd[4]	$ 500,000	12.0%	26/11/2026[8]	Unsecured
P K W Superannuation Pty Ltd[5,7]	$ 100,000	10.0%	26/11/2026[8]	Unsecured
Paul Wright	$ 25,000	12.0%	26/11/2026[8]	Unsecured
Beachridge Advisory[6]	$ 25,000	12.0%	26/11/2026[8]	Unsecured
Non-Related Parties Convertible Note[7]	$ 200,000	10.0%	11/10/2026	Unsecured

[1] John W King Nominees is a company associated with Julie King, a Non-Executive Director of the Company.

[2] Invia Custodian Pty Limited is a company associated with Paul Lewis, a Non-Executive Director of the Company.

[3] PAJ Lewis Pty Ltd is a company associated with Paul Lewis, a Non-Executive Director of the Company.

[4] PAJ Lewis Superannuation Fund Pty Ltd is a company associated with Paul Lewis, a Non-Executive Director of the Company

[5] P K W Superannuation Pty Ltd is a company associated with Paul Wright, a Non-Executive Director of the Company.

[6] Beachridge Advisory is a company associated with Gavin Coote, an Executive Director of the Company.

[7] These loans represent Convertible Notes held in Hydrix Limited.

[8] Loans are to be converted to equity, subject to approval at the Hydrix Limited AGM on 26th November 2026

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,146)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,495
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,495
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**1.30**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: No. Net Cash from Operating Activities in the quarter were impacted by delayed receipts from customers who are raising capital to fund their projects and projects tied to milestone payments. We anticipate these customer receipts will be brought up to date in the upcoming December quarter. There were also one-off cash payments in the quarter relating to the June quarter capital raise and the shift from quarterly superannuation payments to monthly from 1 July resulting in two quarters of superannuation paid in the quarter. Adjusting for timing impacts of customer receipts and one-off payments, the estimated quarters of funding available is greater than 2 quarters cash on hand on 30 September 2026.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: The Board continuously considers the Company's funding requirements to support working capital and execution of its growth strategy, including Defence IP initiatives.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes, based on current trading assumptions. The Board and management consider the current assumptions to be reasonable based on available information and anticipates being able to continue operations and meet business objectives. The Board continues to monitor these assumptions and the Group's operating performance.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 29 October 2026

Authorised by: Board of Directors of Hydrix Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.